Objective: Many thyroid cancer patients are exposed to long-term thyroid stimulating hormone (TSH) suppression, often as lifetime treatment, and are consequently at risk for cardiovascular disease. We investigated the incidence of coronary heart disease (CHD) and ischemic stroke among thyroid cancer patients compared with matched control subjects.
INTRODUCTION
Thyroid stimulating hormone (TSH) suppression using levothyroxine is routinely prescribed to reduce thyroid cancer recurrence after total thyroidectomy with or without radioactive iodine (RAI) ablation.
1, 2 Previous US 1 and European 2 guidelines recommended TSH suppression of <0.1 mIU/L for high-risk thyroid cancer patients and between 0.1 and 1-2 mIU/L for low-risk patients and most thyroid cancer patients have been exposed to long-term TSH suppression, in many cases as lifetime treatment.
Hyperthyroidism due to thyroid disease is a well-known risk factor for atrial fibrillation 3 and ischemic stroke, 4 and may also precipitate angina or myocardial infarction in patients with underlying coronary heart disease (CHD). 5 Similarly, overt or subclinical hyperthyroidism due to supraphysiologic doses of levothyroxine for TSH suppression may also have adverse cardiovascular effects, 6 including atrial fibrillation, 7 diastolic dysfunction, 8 and left ventricular hypertrophy. 9 Small hospital-based studies in the US (n=524) and Finland (n=901) reported increased cardiovascular mortality or incidence in patients with differentiated thyroid cancer compared to controls chosen from other cohorts, particularly in those with low TSH levels, 10, 11 but large-scale data on a population level are lacking.
We therefore conducted a large cohort study to investigate the incidence of CHD and ischemic stroke among post-thyroidectomy thyroid cancer patients compared with noncancer controls and explored the possible pathophysiological mechanisms involved.
SUBJECTS AND METHODS

Study Population
We conducted a retrospective cohort study based on the Korean National Health Insurance respectively, for risk of ischemic stroke (Figure 3) .
Risk of Atrial Fibrillation in Thyroid Cancer Patients
Thyroid cancer patients were also more likely to develop atrial fibrillation when the recommendations for regular atrial fibrillation screening it may be warranted after thyroidectomy in those taking levothyroxine, and once atrial fibrillation is detected these patients would likely benefit from more aggressive stroke prevention measures, including anticoagulant medication. 25, 26 Future studies are needed to determine the most appropriate approach to screening and management of atrial fibrillation in thyroid cancer patients.
However, it appears that ischemic stroke associated with atrial fibrillation accounts for only a small proportion of ischemic stroke incidence (4.4%, 128/2914) and patients who took a higher levothyroxine dosage but did not develop atrial fibrillation also had a 1.5 times higher risk of developing ischemic stroke, suggesting that other pathophysiologic pathways may be involved independent of cardioembolic stroke. Systolic hypertension, arterial stiffness, and hypercoagulability were suggested as potential mechanisms 22 and warrant further investigation. Although atrial fibrillation is often undiagnosed and not claimed for medical treatment, it is routinely checked upon occurrence of ischemic stroke. A low incidence of atrial fibrillation even in patients who developed ischemic stroke, together with our generally younger, predominantly female population, suggest that atrial fibrillation is not a main factor associated with ischemic stroke. (approximately 40-200 USD), mainly through private health screening programs. This explains why our study subjects were in higher income ranks compared with the general population. Those who elect to receive health screening are more likely to be engaged in healthier behavior (e.g., not smoking) and receive more attentive preventive treatment (e.g., antihypertensive agents, statins, and aspirin). 16 When considering this screenee effect, our estimation of increased cardiovascular risk is likely to be conservative. A similar J-shaped risk pattern was also observed for fracture in our previous study.
14 Although the data are inconclusive due to the small number of thyroid cancer patients who received unilateral thyroidectomy, it appears that the risk of developing CHD and ischemic stroke is not evidently increased in this group. Until recently, surgeons tended to favor total thyroidectomy due to the fear of recurrence and for the ease of postsurgical radioactive iodine ablation and follow-up with thyroglobulin. 2 Indeed, only 3.6% of all thyroid cancer patients in our study received unilateral lobectomy, and the situation is not much different in other countries such as in the United States, where 75% of those with papillary 
